Disorders Due to Cannabis Use: Complete ICD-11 Coding Guide
1. Introduction
Disorders due to cannabis use represent a set of clinical conditions resulting from the consumption of psychoactive preparations derived from the Cannabis sativa plant and its variants. With the increasing legalization and decriminalization of cannabis in various jurisdictions worldwide, there is a significant increase in the prevalence of these disorders, making adequate knowledge about their classification and coding essential.
Cannabis contains more than 100 different cannabinoids, with δ-9-tetrahydrocannabinol (THC) being the main psychoactive component responsible for effects on the central nervous system. These compounds interact with endogenous cannabinoid receptors, modulating the release of neurotransmitters and producing effects ranging from euphoria and relaxation to significant cognitive and psychomotor impairments.
The clinical importance of these disorders lies not only in their increasing prevalence, but also in the substantial impact on public health. Users may develop dependence, experience withdrawal symptoms, and present various substance-induced mental disorders. Correct coding using ICD-11 is critical for adequate therapeutic planning, allocation of health resources, epidemiological research, and effective communication among health professionals. Furthermore, accurate documentation allows for monitoring of population trends and evaluation of the effectiveness of public policies related to psychoactive substance use.
2. Correct ICD-11 Code
Code: 6C41
Description: Disorders due to use of cannabis
Parent category: Disorders due to substance use
Official definition: Disorders due to use of cannabis are characterized by the pattern and consequences of cannabis use. Cannabis is the collective term for a range of psychoactive preparations of the plant Cannabis sativa, and related species and hybrids. Cannabis contains cannabinoids, a class of diverse chemical components that act on endogenous cannabinoid receptors that modulate the release of neurotransmitters in the brain.
The main psychoactive cannabinoid is δ-9-tetrahydrocannabinol (THC). Cannabis is typically smoked in the form of flowers or leaves of the marijuana plant, often mixed with tobacco. There are also cannabis oils prepared from these same sources, with preparations that vary considerably in relation to THC potency.
Cannabis has predominantly depressant effects on the central nervous system and produces a characteristic euphoria that may be part of the clinical presentation in intoxication. The substance has properties that produce dependence, resulting in cannabis dependence in some people and withdrawal when use is reduced or discontinued. Cannabis is associated with a range of induced mental disorders.
3. When to Use This Code
Code 6C41 should be applied in specific clinical scenarios where the use of natural cannabis (derived from the plant) results in identifiable disorders. Below are detailed practical situations:
Scenario 1: Established Dependence with Functional Impairment A 28-year-old patient presents with daily cannabis use for 5 years, smoking between 3 to 5 marijuana cigarettes per day. Reports multiple failed attempts to cease use, experiences intense craving when attempting to stop, and presents with impairment in work performance, with frequent absences from work. The pattern of use has become prioritized in his routine, neglecting other previously pleasurable activities.
Scenario 2: Acute Intoxication Requiring Care An individual arrives at the emergency department presenting with severe anxiety, tachycardia, paranoid ideation, and temporal disorientation following consumption of high-potency cannabis. Examination reveals hyperemic conjunctivae, dry mouth, impairment in motor coordination, and perceptual alterations. Cannabis intoxication is causing clinically significant distress.
Scenario 3: Withdrawal Syndrome A patient undergoing treatment for cannabis dependence, after 8 years of regular use, presents with marked irritability, severe insomnia, loss of appetite, restlessness, diaphoresis, and fine tremors after 48 hours of cessation. The symptoms are sufficiently severe to cause significant distress and interfere with daily activities.
Scenario 4: Cannabis-Induced Psychotic Disorder A chronic cannabis user develops psychotic symptoms including auditory hallucinations and persecutory delusions that emerge during or shortly after intense substance use. The symptoms exceed those typically associated with simple intoxication and persist for several days, requiring psychiatric intervention.
Scenario 5: Cannabis-Induced Anxiety Disorder A patient presents with recurrent panic attacks and generalized anxiety that developed temporally related to the onset of regular cannabis use. The symptoms are sufficiently severe to warrant independent clinical attention and are not better explained by another primary mental disorder.
Scenario 6: Harmful Use with Health Consequences An individual with a pattern of use that has resulted in damage to physical health (chronic bronchitis, persistent cough) or mental health (recurrent depressive episodes), but who does not yet meet full criteria for dependence. Use continues despite knowledge of the harm caused.
4. When NOT to Use This Code
It is fundamental to distinguish situations where code 6C41 is not appropriate:
Use of Synthetic Cannabinoids: If the patient uses synthetic substances such as "spice" or "K2" (synthetic cannabinoids), the correct code is 6C42 - Disorders due to use of synthetic cannabinoids. These substances, although they act on cannabinoid receptors similar to those of natural cannabis, have a distinct profile of effects, potency, and risks compared to natural cannabis.
Hazardous Use without Established Disorder: When there is a pattern of use that substantially increases the risk of harmful consequences (such as driving under the influence), but has not yet resulted in a diagnosable disorder, the code for hazardous cannabis use should be used. Hazardous use is characterized by potential risk, not by the presence of dependence symptoms or other disorders.
Supervised Medicinal Use: Patients using cannabis preparations or cannabinoids under prescription and adequate medical supervision, without developing a problematic pattern of use, should not receive this code. Controlled therapeutic use does not constitute a disorder.
Occasional Experimentation without Consequences: Sporadic, experimental, or recreational use that does not result in functional impairment, dependence, or other disorders does not justify coding. Mere exposure to the substance, without significant clinical consequences, does not constitute a disorder.
Primary Mental Disorders: When psychiatric symptoms exist independently of cannabis use or clearly precede the onset of use, the primary diagnosis should be the specific mental disorder, with cannabis use being coded separately only if it constitutes an additional clinical problem.
5. Step-by-Step Coding Process
Step 1: Assess Diagnostic Criteria
Diagnostic confirmation requires systematic and comprehensive evaluation. Begin with a detailed history of the pattern of use: frequency, quantity, route of administration, duration of use, cessation attempts, and contexts of use. Investigate the presence of dependence symptoms, including tolerance (need for progressively larger amounts), withdrawal, loss of control, excessive time spent obtaining and using, and continuation despite negative consequences.
Use validated instruments such as the Cannabis Use Disorder Identification Test (CUDIT) or structured interviews to assess diagnostic criteria. Examine functional impairment in vital areas: occupational, academic, social, and family. Document consequences to physical and mental health. Consider toxicological testing when appropriate, although diagnosis is fundamentally clinical.
Also assess the presence of psychiatric comorbidities and concomitant use of other substances, as these are frequent situations that impact treatment and prognosis.
Step 2: Verify Specifiers
ICD-11 allows important specifications that refine the diagnosis. Determine the temporal pattern: current episode, early remission (1-12 months without criteria), or sustained remission (more than 12 months). Identify which specific manifestation is present: single episode of intoxication, harmful use, dependence, withdrawal, or induced mental disorder.
For dependence, assess severity considering the number of criteria met and the degree of functional impairment. For induced mental disorders, specify the type: psychotic, anxious, depressive, or other. Document course characteristics, such as continuous versus intermittent pattern.
Also consider relevant contextual specifiers, such as use in controlled (institutional) versus uncontrolled environments.
Step 3: Differentiate from Other Codes
6C40 - Disorders due to use of alcohol: The fundamental difference lies in the substance used. Although both may present similar patterns of dependence and intoxication, the pharmacological effects are distinct. Cannabis produces characteristic euphoria, perceptual alterations, hyperemic conjunctivae, and specific psychomotor impairment, while alcohol causes disinhibition, motor incoordination, and can lead to potentially fatal intoxication. Cannabis withdrawal is generally milder than alcohol withdrawal, which may include seizures and delirium.
6C42 - Disorders due to use of synthetic cannabinoids: This category applies specifically to synthetic substances that mimic cannabinoid effects but have different chemical structure. Synthetic cannabinoids frequently present much greater potency, more unpredictable effects, and risks of more severe acute toxicity, including seizures, rhabdomyolysis, and severe cardiovascular events, rarely seen with natural cannabis.
6C43 - Disorders due to use of opioids: Opioids produce potent analgesia, profound sedation, pupillary miosis (versus mydriasis or red eyes in cannabis), and significant risk of fatal respiratory depression. Opioid dependence is generally more severe, with physically more intense withdrawal and greater risk of fatal overdose, characteristics distinct from cannabis use disorders.
Step 4: Required Documentation
Meticulously document the following elements:
Mandatory Checklist:
- Specific substance used (type of cannabis preparation)
- Pattern of use: frequency, quantity, duration, route of administration
- Specific diagnostic criteria met
- Functional impairment in different areas of life
- Previous cessation attempts and their outcomes
- Withdrawal symptoms experienced (if applicable)
- Medical and psychiatric comorbidities
- Concomitant use of other substances
- Social, occupational, and legal consequences
- Results of toxicological testing (when performed)
- Assessments with standardized instruments
- Proposed therapeutic plan
Record clear justification for the code chosen, differentiating from alternative diagnoses considered. Document cultural and social context when relevant to case understanding.
6. Complete Practical Example
Clinical Case
Initial Presentation: A 32-year-old technology professional seeks outpatient care at family's request. Reports cannabis use initiated at age 19, recreationally in social contexts, gradually progressing to daily use approximately 6 years ago. Currently smokes cannabis 4-6 times daily, beginning in the morning before work.
Over the past 2 years, the patient notes that he needs to increase the amount consumed to obtain the same desired relaxation effects. He made three cessation attempts in the past year, the longest lasting 10 days, all interrupted by intense craving, marked irritability, and severe insomnia. He describes that use has become "automatic," consuming even when he plans not to.
Evaluation Performed: During the interview, the patient demonstrates partial insight into his problem. He reports impairment in work performance, with difficulties in concentration and recent memory, resulting in workplace warnings. Family relationships have deteriorated, with frequent conflicts related to use. He abandoned previously enjoyable hobbies (sports practice, playing a musical instrument) to dedicate time to use.
Mental status examination: alert, oriented, coherent speech but with slowed thinking. Euthymic mood, but reports frequent episodes of anxiety and irritability when unable to use cannabis. Denies psychotic symptoms. Physical examination reveals chronic cough and chronically hyperemic conjunctivae.
CUDIT application reveals a score indicative of severe dependence. Denies problematic use of other substances, occasional social alcohol consumption. Positive family history for substance use disorders (father with alcohol dependence).
Diagnostic Reasoning: The patient meets multiple criteria for cannabis dependence: evident tolerance, withdrawal symptoms when attempting to stop, loss of control over use, significant time dedicated to use, continuation despite negative consequences (occupational and family problems), and reduction of important activities. Functional impairment is substantial and clinically significant.
There is no evidence of synthetic cannabinoid use, only natural cannabis. The symptoms are not better explained by another primary mental disorder, although anxiety and irritability are present, they appear secondary to the pattern of use and withdrawal.
Coding Justification: The code 6C41 - Disorders due to cannabis use is appropriate, specifically with specifier for cannabis dependence, continuous pattern, moderate to severe severity. The choice is based on the specific substance (natural cannabis, not synthetic), presence of multiple dependence criteria, significant functional impairment, and absence of features that would indicate alternative codes.
Step-by-Step Coding:
- Confirmation of substance: natural cannabis (smoked flowers)
- Identification of disorder: established dependence
- Exclusion of alternatives: not synthetic cannabinoid (6C42), not merely hazardous use
- Specification: dependence, continuous pattern, current use
- Final code: 6C41 with appropriate specifiers
Complementary Codes:
- Chronic cough related to smoking may justify additional respiratory system code
- If a more clearly defined induced anxiety disorder developed, it could be coded additionally
7. Related Codes and Differentiation
Within the Same Category
6C40: Disorders due to alcohol use
When to use vs. 6C41: Use 6C40 when the primary problematic substance is alcohol, not cannabis. Patients may use both substances, a situation that requires multiple coding if both use patterns meet criteria for disorders.
Main difference: The psychoactive substance and its characteristic effects. Alcohol produces behavioral disinhibition, gross motor incoordination, slurred speech, and can cause fatal intoxication. Alcohol withdrawal is potentially severe, with risk of seizures and delirium tremens. Cannabis produces euphoria, subtle perceptual alterations, red eyes, and specific cognitive impairment, with withdrawal generally milder.
6C42: Disorders due to synthetic cannabinoid use
When to use vs. 6C41: Use 6C42 specifically when the patient uses synthetic cannabinoids (synthetic chemical substances that mimic THC but with different molecular structure), marketed as "incense," "spice," "K2," or other names.
Main difference: Synthetic cannabinoids are substances completely manufactured in the laboratory, not derived from the cannabis plant. They present potency often much greater, more unpredictable effects, and a distinct toxicity profile, including increased risk of acute cardiovascular events, seizures, and severe psychosis. The risk profile is substantially different from natural cannabis.
6C43: Disorders due to opioid use
When to use vs. 6C41: Apply 6C43 when the problematic substance belongs to the opioid class (morphine, heroin, codeine, oxycodone, fentanyl, etc.), not cannabis.
Main difference: Opioids are central nervous system depressants with a completely different mechanism of action (mu, kappa, and delta opioid receptors versus CB1 and CB2 cannabinoid receptors). They produce potent analgesia, profound sedation, pupillary miosis, and significant risk of fatal respiratory depression. Opioid dependence is generally more severe, with physically intense withdrawal (muscle aches, vomiting, diarrhea) and greater risk of lethal overdose.
Differential Diagnoses
Primary Psychotic Disorders: Schizophrenia or other psychotic disorders may coexist with cannabis use or be confused with cannabis-induced psychosis. The distinction is based on temporality (do psychotic symptoms persist significantly beyond intoxication and withdrawal?), prior history (did symptoms exist before use?), and symptom pattern.
Primary Anxiety Disorders: Anxiety may be a symptom of intoxication, withdrawal, or cannabis-induced disorder, but may also be a primary disorder. Assess whether anxiety precedes cannabis use, persists during periods of prolonged abstinence, and presents with characteristics not typical of cannabinoid effects.
Attention-Deficit Disorder: Cognitive and attention impairments are common in chronic cannabis use but should be differentiated from primary ADHD through developmental history, presence of symptoms in childhood, and pattern of impairments.
8. Differences with ICD-10
In ICD-10, cannabis-related disorders were coded in category F12, with subdivisions such as F12.0 (acute intoxication), F12.1 (harmful use), F12.2 (dependence syndrome), F12.3 (withdrawal syndrome), among others.
ICD-11 represents a significant paradigm shift. Code 6C41 unifies all disorders due to cannabis use under a main category, with specifiers to differentiate specific manifestations, rather than separate codes for each presentation. This approach better reflects contemporary understanding that these conditions represent a related spectrum of a substance use disorder.
Main changes include: more explicit recognition of cannabis withdrawal syndrome (previously controversial), revised diagnostic criteria for dependence based on updated evidence, and clear distinction between natural cannabis and synthetic cannabinoids (which in ICD-10 were often grouped together).
The practical impact of these changes includes greater flexibility in coding, better capture of clinical complexity, and facilitation of epidemiological research and international comparisons. Professionals should familiarize themselves with the hierarchical structure of ICD-11 and the appropriate use of specifiers for complete documentation.
9. Frequently Asked Questions
How is the diagnosis of disorders due to cannabis use made?
The diagnosis is fundamentally clinical, based on comprehensive evaluation by a qualified professional. It begins with a detailed interview about use pattern, consumption history, cessation attempts, and consequences. Mental and physical examination are essential. Standardized instruments such as CUDIT, ASSIST, or structured interviews aid in systematic evaluation. Toxicological tests can confirm recent use but do not establish a diagnosis of disorder, as use does not automatically equate to disorder. The presence of specific criteria (loss of control, tolerance, withdrawal, functional impairment) and clinically significant distress are necessary for formal diagnosis.
Is treatment available in public health systems?
The availability of treatment varies considerably among different regions and health systems. Many public health systems offer some level of treatment for substance use disorders, including cannabis, typically through mental health services or specialized chemical dependency programs. Treatment may include psychosocial interventions (cognitive-behavioral therapy, motivational interviewing, contingency management), support groups, and in some cases, medications for specific symptoms. The extent and quality of services vary significantly, with some systems offering comprehensive programs and others with limited resources.
How long does treatment last?
Treatment duration is highly individualized, depending on the severity of dependence, presence of comorbidities, treatment response, and personal circumstances. Brief interventions may be sufficient for mild cases, lasting a few weeks. Moderate to severe dependence typically requires more prolonged treatment, often 3-6 months of intensive intervention, followed by maintenance follow-up that may extend for years. Recovery is a continuous process, and many individuals benefit from long-term support to prevent relapse. There is no universal "standard" duration; treatment should be adjusted to each patient's specific needs.
Can this code be used in medical certificates?
The use of diagnostic codes in medical certificates requires careful consideration of ethical and legal issues. In many jurisdictions, certificates to justify occupational absences do not require detailed diagnostic specification, with indication of need for leave for medical reasons being sufficient. When specification is necessary, the use of the ICD code must respect confidentiality and potential consequences for the patient, including stigma and occupational or legal implications. Professionals must balance the need for adequate documentation with protection of patient privacy, using more general descriptions when appropriate.
Can medicinal cannabis cause dependence?
Yes, even supervised medicinal use of cannabis or cannabinoid preparations can result in dependence in some individuals, although the risk is generally lower when use is appropriately prescribed and monitored. Factors that influence risk include dose, THC potency, duration of use, individual vulnerability, and personal or family history of substance use disorders. Appropriately supervised medicinal use minimizes but does not completely eliminate this risk. Patients on medicinal use should be monitored for signs of development of problematic patterns.
What are the symptoms of cannabis withdrawal?
The cannabis withdrawal syndrome, although often milder than withdrawal from alcohol or opioids, is clinically significant. Common symptoms include irritability and anger, anxiety and nervousness, sleep difficulties (insomnia, vivid dreams), decreased appetite and weight loss, restlessness, depressed mood, and physical symptoms such as abdominal discomfort, tremors, sweating, and fever. Symptoms typically begin 24-72 hours after cessation, peak in the first week, and may persist for several weeks. Severity correlates with the intensity and duration of previous use.
Is it possible to have a cannabis use disorder and another substance disorder simultaneously?
Absolutely. Comorbidity of multiple substance use disorders is common. Individuals may simultaneously meet criteria for disorders due to cannabis and alcohol use, for example, or cannabis and stimulants. Each disorder should be coded separately when diagnostic criteria are met. Concomitant use of multiple substances complicates the clinical picture, treatment, and prognosis, often requiring more intensive and specialized therapeutic approach. Careful evaluation of all substances used is essential.
How to differentiate recreational use from disorder?
The fundamental distinction lies in the presence or absence of significant negative consequences and loss of control. Occasional recreational use, without development of tolerance, without withdrawal symptoms, without frustrated attempts to control use, and without functional impairment in important life areas does not constitute a disorder. Disorder is characterized by a problematic pattern with persistent adverse consequences, loss of control over use, prioritization of use over other activities, and continuation despite problems caused. Frequency of use alone does not define disorder; functional impact and presence of specific diagnostic criteria are determinants.
Conclusion: Appropriate coding of disorders due to cannabis use using ICD-11 code 6C41 requires comprehensive understanding of diagnostic criteria, careful differentiation of related conditions, and meticulous documentation. This knowledge is essential for quality clinical practice, effective communication among professionals, and appropriate allocation of therapeutic resources, contributing to better outcomes for patients affected by these disorders.
External References
This article was developed based on reliable scientific sources:
- 🌍 WHO ICD-11 - Disorders due to use of cannabis
- 🔬 PubMed Research on Disorders due to use of cannabis
- 🌍 WHO Health Topics
- 📋 NICE Mental Health Guidelines
- 📊 Clinical Evidence: Disorders due to use of cannabis
- 📋 Ministry of Health - Brazil
- 📊 Cochrane Systematic Reviews
References verified on 2026-02-03